BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Callaghan R, Luk F, Bebawy M. Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy? Drug Metab Dispos 2014;42:623-31. [PMID: 24492893 DOI: 10.1124/dmd.113.056176] [Cited by in Crossref: 207] [Cited by in F6Publishing: 220] [Article Influence: 25.9] [Reference Citation Analysis]
Number Citing Articles
1 Khatoon F, Ali S, Kumar V, Elasbali AM, Alhassan HH, Alharethi SH, Islam A, Hassan MI. Pharmacological features, health benefits and clinical implications of honokiol. Journal of Biomolecular Structure and Dynamics. [DOI: 10.1080/07391102.2022.2120541] [Reference Citation Analysis]
2 Singh A, Yadagiri G, Javaid A, Sharma KK, Verma A, Singh OP, Sundar S, Mudavath SL. Hijacking the intrinsic vitamin B12 pathway for the oral delivery of nanoparticles, resulting in enhanced in vivo anti-leishmanial activity. Biomater Sci 2022. [PMID: 36017751 DOI: 10.1039/d2bm00979j] [Reference Citation Analysis]
3 Paukovcekova S, Krchniakova M, Chlapek P, Neradil J, Skoda J, Veselska R. Thiosemicarbazones Can Act Synergistically with Anthracyclines to Downregulate CHEK1 Expression and Induce DNA Damage in Cell Lines Derived from Pediatric Solid Tumors. IJMS 2022;23:8549. [DOI: 10.3390/ijms23158549] [Reference Citation Analysis]
4 Dechouk LF, Bouchoucha A, Abdi Y, Si Larbi K, Bouzaheur A, Terrachet-bouaziz S. Coordination of new palladium (II) complexes with derived furopyran-3,4‑dione ligands: Synthesis, characterization, redox behaviour, DFT, antimicrobial activity, molecular docking and ADMET studies. Journal of Molecular Structure 2022;1257:132611. [DOI: 10.1016/j.molstruc.2022.132611] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Md S, Alhakamy NA, Sharma P, Ansari MS, Gorain B. Nanocarrier-based co-delivery approaches of chemotherapeutics with natural P-glycoprotein inhibitors in the improvement of multidrug resistance cancer therapy. Journal of Drug Targeting. [DOI: 10.1080/1061186x.2022.2069782] [Reference Citation Analysis]
6 Le M, Trinh DT, Ngo T, Tran-nguyen V, Nguyen D, Hoang T, Nguyen H, Do T, Mai TT, Tran T, Thai K, Tsai F. Chalcone Derivatives as Potential Inhibitors of P-Glycoprotein and NorA: An In Silico and In Vitro Study. BioMed Research International 2022;2022:1-9. [DOI: 10.1155/2022/9982453] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Rachmale M, Rajput N, Jadav T, Sahu AK, Tekade RK, Sengupta P. Implication of metabolomics and transporter modulation based strategies to minimize multidrug resistance and enhance site-specific bioavailability: a needful consideration toward modern anticancer drug discovery. Drug Metab Rev 2022;:1-19. [PMID: 35254954 DOI: 10.1080/03602532.2022.2048007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Mahmoud K, Swidan S, El-nabarawi M, Teaima M. Lipid based nanoparticles as a novel treatment modality for hepatocellular carcinoma: a comprehensive review on targeting and recent advances. J Nanobiotechnol 2022;20. [DOI: 10.1186/s12951-022-01309-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Ramalhete C, Gonçalves BMF, Barbosa F, Duarte N, Ferreira MU. Momordica balsamina: phytochemistry and pharmacological potential of a gifted species. Phytochem Rev. [DOI: 10.1007/s11101-022-09802-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Papaioannou L, Avgoustakis K. Responsive nanomedicines enhanced by or enhancing physical modalities to treat solid cancer tumors: Preclinical and clinical evidence of safety and efficacy. Adv Drug Deliv Rev 2022;181:114075. [PMID: 34883140 DOI: 10.1016/j.addr.2021.114075] [Reference Citation Analysis]
11 Husain A, Makadia V, Valicherla GR, Riyazuddin M, Gayen JR. Approaches to minimize the effects of P-glycoprotein in drug transport: A review. Drug Dev Res 2022. [PMID: 35103340 DOI: 10.1002/ddr.21918] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Bonadio RC, Estevez-Diz MDP. Perspectives on PARP Inhibitor Combinations for Ovarian Cancer. Front Oncol 2021;11:754524. [PMID: 34976801 DOI: 10.3389/fonc.2021.754524] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Kabel AM, Salama SA, Borg HM, Ali DA, Abd Elmaaboud MA. Targeting p-AKT/mTOR/MAP kinase signaling, NLRP3 inflammasome and apoptosis by fluvastatin with or without taxifolin mitigates gonadal dysfunction induced by bisphenol-A in male rats. Hum Exp Toxicol 2022;41:9603271221089919. [PMID: 35465754 DOI: 10.1177/09603271221089919] [Reference Citation Analysis]
14 Nandi SK, Roychowdhury T, Chattopadhyay S, Basu S, Chatterjee K, Choudhury P, Banerjee N, Saha P, Mukhopadhyay S, Mukhopadhyay A, Bhattacharya R. Deregulation of the CD44-NANOG-MDR1 associated chemoresistance pathways of breast cancer stem cells potentiates the anti-cancer effect of Kaempferol in synergism with Verapamil. Toxicology and Applied Pharmacology 2022. [DOI: 10.1016/j.taap.2022.115887] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
15 Brindangnanam P, Sawant AR, Prashanth K, Coumar MS. Bacterial effluxome as a barrier against antimicrobial agents: structural biology aspects and drug targeting. Tissue Barriers 2021;:2013695. [PMID: 34957912 DOI: 10.1080/21688370.2021.2013695] [Reference Citation Analysis]
16 Huang W, Zhang J, Dong B, Chen H, Shao L, Li X. A Novel miR-98 Negatively Regulates the Resistance of Endometrial Cancer Cells to Paclitaxel by Suppressing ABCC10/MRP-7. Front Oncol 2021;11:809410. [PMID: 34950596 DOI: 10.3389/fonc.2021.809410] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
17 Winkelman MA, Kim DY, Kakarla S, Grath A, Silvia N, Dai G. Interstitial flow enhances the formation, connectivity, and function of 3D brain microvascular networks generated within a microfluidic device. Lab Chip 2021;22:170-92. [PMID: 34881385 DOI: 10.1039/d1lc00605c] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
18 Grabarnick Portnoy E, Andriyanov AV, Han H, Eyal S, Barenholz Y. PEGylated Liposomes Remotely Loaded with the Combination of Doxorubicin, Quinine, and Indocyanine Green Enable Successful Treatment of Multidrug-Resistant Tumors. Pharmaceutics 2021;13:2181. [PMID: 34959462 DOI: 10.3390/pharmaceutics13122181] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
19 Filipczak N, Joshi U, Attia SA, Berger Fridman I, Cohen S, Konry T, Torchilin V. Hypoxia-sensitive drug delivery to tumors. J Control Release 2021;341:431-42. [PMID: 34838607 DOI: 10.1016/j.jconrel.2021.11.034] [Reference Citation Analysis]
20 Teng YN, Huang BH, Huang SY, Wu IT, Wu TS, Lee TE, Hung CC. Cinnamophilin overcomes cancer multi-drug resistance via allosterically modulating human P-glycoprotein on both drug binding sites and ATPase binding sites. Biomed Pharmacother 2021;144:112379. [PMID: 34794239 DOI: 10.1016/j.biopha.2021.112379] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Abd-Ellatef GEF, Gazzano E, El-Desoky AH, Hamed AR, Kopecka J, Belisario DC, Costamagna C, S Marie MA, Fahmy SR, Abdel-Hamid AZ, Riganti C. Glabratephrin reverses doxorubicin resistance in triple negative breast cancer by inhibiting P-glycoprotein. Pharmacol Res 2021;175:105975. [PMID: 34785319 DOI: 10.1016/j.phrs.2021.105975] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Halder J, Pradhan D, Kar B, Ghosh G, Rath G. Nanotherapeutics approaches to overcome P-glycoprotein-mediated multi-drug resistance in cancer. Nanomedicine 2021;:102494. [PMID: 34775061 DOI: 10.1016/j.nano.2021.102494] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
23 Hasan A, Tang D, Nijat D, Yang H, Aisa HA. Diterpenoids from Euphorbia glomerulans with potential reversal activities against P-glycoprotein-mediated multidrug resistance. Bioorg Chem 2021;117:105442. [PMID: 34742027 DOI: 10.1016/j.bioorg.2021.105442] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Prihantono, Faruk M. Breast cancer resistance to chemotherapy: When should we suspect it and how can we prevent it? Ann Med Surg (Lond) 2021;70:102793. [PMID: 34691411 DOI: 10.1016/j.amsu.2021.102793] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
25 Mdlovu NV, Lin KS, Weng MT, Lin YS. Design of doxorubicin encapsulated pH-/thermo-responsive and cationic shell-crosslinked magnetic drug delivery system. Colloids Surf B Biointerfaces 2021;209:112168. [PMID: 34715504 DOI: 10.1016/j.colsurfb.2021.112168] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
26 Yuan S, Wang B, Dai QQ, Zhang XN, Zhang JY, Zuo JH, Liu H, Chen ZS, Li GB, Wang S, Liu HM, Yu B. Discovery of New 4-Indolyl Quinazoline Derivatives as Highly Potent and Orally Bioavailable P-Glycoprotein Inhibitors. J Med Chem 2021;64:14895-911. [PMID: 34546748 DOI: 10.1021/acs.jmedchem.1c01452] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
27 Wang L, O'Mara ML. Effect of the Force Field on Molecular Dynamics Simulations of the Multidrug Efflux Protein P-Glycoprotein. J Chem Theory Comput 2021;17:6491-508. [PMID: 34506133 DOI: 10.1021/acs.jctc.1c00414] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
28 Balli OI, Uversky VN, Durdagi S, Coskuner-Weber O. Challenges and limitations in the studies of glycoproteins: A computational chemist's perspective. Proteins 2021. [PMID: 34549826 DOI: 10.1002/prot.26242] [Reference Citation Analysis]
29 El-Wakil MH, Teleb M. Transforming Type II to Type I c-Met kinase inhibitors via combined scaffold hopping and structure-guided synthesis of new series of 1,3,4-thiadiazolo[2,3-c]-1,2,4-triazin-4-one derivatives. Bioorg Chem 2021;116:105304. [PMID: 34534756 DOI: 10.1016/j.bioorg.2021.105304] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Yu KH, Hung CC, Wu TS, Chen CF, Wu IT, Kuo PC, Lam SH, Hung HY. Chemoreversal Agents from Taiwanofungus Genus and Their More Potent Methyl Derivatives Targeting Signal Transducer and Activator of Transcription 3 (STAT3) Phosphorylation. Pharmaceuticals (Basel) 2021;14:916. [PMID: 34577615 DOI: 10.3390/ph14090916] [Reference Citation Analysis]
31 El-Wakil MH, Teleb M, Abu-Serie MM, Huang S, Zamponi GW, Fahmy H. Structural optimization, synthesis and in vitro synergistic anticancer activities of combinations of new N3-substituted dihydropyrimidine calcium channel blockers with cisplatin and etoposide. Bioorg Chem 2021;115:105262. [PMID: 34411980 DOI: 10.1016/j.bioorg.2021.105262] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
32 McQuerry JA, Chen J, Chang JT, Bild AH. Tepoxalin increases chemotherapy efficacy in drug-resistant breast cancer cells overexpressing the multidrug transporter gene ABCB1. Transl Oncol 2021;14:101181. [PMID: 34298440 DOI: 10.1016/j.tranon.2021.101181] [Reference Citation Analysis]
33 Markowicz-Piasecka M, Huttunen J, Montaser A, Adla SK, Auriola S, Lehtonen M, Huttunen KM. Ganciclovir and Its Hemocompatible More Lipophilic Derivative Can Enhance the Apoptotic Effects of Methotrexate by Inhibiting Breast Cancer Resistance Protein (BCRP). Int J Mol Sci 2021;22:7727. [PMID: 34299347 DOI: 10.3390/ijms22147727] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
34 Park M, Hwang JW, Cho Y, Kim S, Han SH, Yu J, Ha S, Kim WY, Kim SN, Kim IS, Kim YK. A novel synthetic microtubule inhibitor exerts antiproliferative effects in multidrug resistant cancer cells and cancer stem cells. Sci Rep 2021;11:10822. [PMID: 34031528 DOI: 10.1038/s41598-021-90337-w] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
35 Lahmar A, Mathey A, Aires V, Elgueder D, Vejux A, Khlifi R, Sioud F, Chekir-Ghedira L, Delmas D. Essential Oils, Pituranthos chloranthus and Teucrium ramosissimum, Chemosensitize Resistant Human Uterine Sarcoma MES-SA/Dx5 Cells to Doxorubicin by Inducing Apoptosis and Targeting P-Glycoprotein. Nutrients 2021;13:1719. [PMID: 34069490 DOI: 10.3390/nu13051719] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
36 Abbasi M, Ghoran SH, Niakan MH, Jamali K, Moeini Z, Jangjou A, Izadpanah P, Amani AM. Mesoporous silica nanoparticle: Heralding a brighter future in cancer nanomedicine. Microporous and Mesoporous Materials 2021;319:110967. [DOI: 10.1016/j.micromeso.2021.110967] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
37 Parvathaneni V, Elbatanony RS, Shukla SK, Kulkarni NS, Kanabar DD, Chauhan G, Ayehunie S, Chen Z, Muth A, Gupta V. Bypassing P-glycoprotein mediated efflux of afatinib by cyclodextrin complexation – Evaluation of intestinal absorption and anti-cancer activity. Journal of Molecular Liquids 2021;327:114866. [DOI: 10.1016/j.molliq.2020.114866] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
38 Shawky AM, Abdalla AN, Ibrahim NA, Abourehab MAS, Gouda AM. Discovery of new pyrimidopyrrolizine/indolizine-based derivatives as P-glycoprotein inhibitors: Design, synthesis, cytotoxicity, and MDR reversal activities. Eur J Med Chem 2021;218:113403. [PMID: 33823396 DOI: 10.1016/j.ejmech.2021.113403] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
39 Omidi Y, Kianinejad N, Kwon Y, Omidian H. Drug delivery and targeting to brain tumors: considerations for crossing the blood-brain barrier. Expert Rev Clin Pharmacol 2021;14:357-81. [PMID: 33554678 DOI: 10.1080/17512433.2021.1887729] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
40 Das T, Anand U, Pandey SK, Ashby CR Jr, Assaraf YG, Chen ZS, Dey A. Therapeutic strategies to overcome taxane resistance in cancer. Drug Resist Updat 2021;55:100754. [PMID: 33691261 DOI: 10.1016/j.drup.2021.100754] [Cited by in Crossref: 4] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
41 Xu Y, Wang S, Yang L, Dong Y, Zhang Y, Yan G, Tang R. pH-sensitive micelles self-assembled from star-shaped TPGS copolymers with ortho ester linkages for enhanced MDR reversal and chemotherapy. Asian J Pharm Sci 2021;16:363-73. [PMID: 34276824 DOI: 10.1016/j.ajps.2021.01.002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
42 Yang SJ, An JH, Park SM, Lee JH, Chae HK, Lee KM, Song WJ, Youn HY. Enhanced expression of cyclooxygenase-2 related multi-drug resistance gene in melanoma and osteosarcoma cell lines by TSG-6 secreted from canine adipose-derived mesenchymal stem/stromal cells. Vet Med Sci 2021;7:968-78. [PMID: 33570264 DOI: 10.1002/vms3.442] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
43 Mynott RL, Wallington-Beddoe CT. Inhibition of P-Glycoprotein Does Not Increase the Efficacy of Proteasome Inhibitors in Multiple Myeloma Cells. ACS Pharmacol Transl Sci 2021;4:713-29. [PMID: 33860196 DOI: 10.1021/acsptsci.0c00200] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
44 Semaan L, Zeng Q, Lu Y, Zhang Y, Zreik MM, Chamseddine MB, Chopp M, Zhang ZG, Moonka D. MicroRNA-214 enriched exosomes from human cerebral endothelial cells (hCEC) sensitize hepatocellular carcinoma to anti-cancer drugs. Oncotarget 2021;12:185-98. [PMID: 33613846 DOI: 10.18632/oncotarget.27879] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
45 Khatoon R, Alam MA, Sharma PK. Current approaches and prospective drug targeting to brain. Journal of Drug Delivery Science and Technology 2021;61:102098. [DOI: 10.1016/j.jddst.2020.102098] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Wang H, Liang Y, Yin Y, Zhang J, Su W, White AM, Bin Jiang, Xu J, Zhang Y, Stewart S, Lu X, He X. Carbon nano-onion-mediated dual targeting of P-selectin and P-glycoprotein to overcome cancer drug resistance. Nat Commun 2021;12:312. [PMID: 33436622 DOI: 10.1038/s41467-020-20588-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
47 Kahya U, Köseer AS, Dubrovska A. Amino Acid Transporters on the Guard of Cell Genome and Epigenome. Cancers (Basel) 2021;13:E125. [PMID: 33401748 DOI: 10.3390/cancers13010125] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
48 Gopisetty MK, Adamecz DI, Nagy FI, Baji Á, Lathira V, Szabó MR, Gáspár R, Csont T, Frank É, Kiricsi M. Androstano-arylpyrimidines: Novel small molecule inhibitors of MDR1 for sensitizing multidrug-resistant breast cancer cells. Eur J Pharm Sci 2021;156:105587. [PMID: 33039566 DOI: 10.1016/j.ejps.2020.105587] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
49 Courageot MP, Duca L, Martiny L, Devarenne-Charpentier E, Morjani H, El Btaouri H. Thrombospondin-1 Receptor CD47 Overexpression Contributes to P-Glycoprotein-Mediated Multidrug Resistance Against Doxorubicin in Thyroid Carcinoma FTC-133 Cells. Front Oncol 2020;10:551228. [PMID: 33365267 DOI: 10.3389/fonc.2020.551228] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
50 Contino M, Guglielmo S, Riganti C, Antonello G, Perrone MG, Giampietro R, Rolando B, Fruttero R, Colabufo NA. One molecule two goals: A selective P-glycoprotein modulator increases drug transport across gastro-intestinal barrier and recovers doxorubicin toxicity in multidrug resistant cancer cells. European Journal of Medicinal Chemistry 2020;208:112843. [DOI: 10.1016/j.ejmech.2020.112843] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
51 de Trizio I, Errede M, d'Amati A, Girolamo F, Virgintino D. Expression of P-gp in Glioblastoma: What we can Learn from Brain Development. Curr Pharm Des 2020;26:1428-37. [PMID: 32186270 DOI: 10.2174/1381612826666200318130625] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
52 Maloney SM, Hoover CA, Morejon-Lasso LV, Prosperi JR. Mechanisms of Taxane Resistance. Cancers (Basel). 2020;12. [PMID: 33182737 DOI: 10.3390/cancers12113323] [Cited by in Crossref: 10] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
53 Joshi U, Filipczak N, Khan MM, Attia SA, Torchilin V. Hypoxia-sensitive micellar nanoparticles for co-delivery of siRNA and chemotherapeutics to overcome multi-drug resistance in tumor cells. International Journal of Pharmaceutics 2020;590:119915. [DOI: 10.1016/j.ijpharm.2020.119915] [Cited by in Crossref: 10] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
54 Afonso de Lima C, de Souza Bueno IL, Nunes Siqueira Vasconcelos S, Sciani JM, Ruiz ALTG, Foglio MA, Carvalho JE, Barbarini Longato G. Reversal of Ovarian Cancer Cell Lines Multidrug Resistance Phenotype by the Association of Apiole with Chemotherapies. Pharmaceuticals (Basel) 2020;13:E327. [PMID: 33096917 DOI: 10.3390/ph13100327] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
55 Löscher W, Gericke B. Novel Intrinsic Mechanisms of Active Drug Extrusion at the Blood-Brain Barrier: Potential Targets for Enhancing Drug Delivery to the Brain? Pharmaceutics 2020;12:E966. [PMID: 33066604 DOI: 10.3390/pharmaceutics12100966] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
56 Vaidya FU, Sufiyan Chhipa A, Mishra V, Gupta VK, Rawat SG, Kumar A, Pathak C. Molecular and cellular paradigms of multidrug resistance in cancer. Cancer Rep (Hoboken) 2020;:e1291. [PMID: 33052041 DOI: 10.1002/cnr2.1291] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
57 Zhang H, Xu H, Ashby CR Jr, Assaraf YG, Chen ZS, Liu HM. Chemical molecular-based approach to overcome multidrug resistance in cancer by targeting P-glycoprotein (P-gp). Med Res Rev 2021;41:525-55. [PMID: 33047304 DOI: 10.1002/med.21739] [Cited by in Crossref: 22] [Cited by in F6Publishing: 54] [Article Influence: 11.0] [Reference Citation Analysis]
58 Mahmud F, Deng S, Chen H, Miller DD, Li W. Orally available tubulin inhibitor VERU-111 enhances antitumor efficacy in paclitaxel-resistant lung cancer. Cancer Lett 2020;495:76-88. [PMID: 32920198 DOI: 10.1016/j.canlet.2020.09.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
59 Shahar N, Larisch S. Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance. Drug Resistance Updates 2020;52:100712. [DOI: 10.1016/j.drup.2020.100712] [Cited by in Crossref: 17] [Cited by in F6Publishing: 40] [Article Influence: 8.5] [Reference Citation Analysis]
60 Jeong YS, Lam TG, Jeong S, Ahn SG. Metformin Derivative HL156A Reverses Multidrug Resistance by Inhibiting HOXC6/ERK1/2 Signaling in Multidrug-Resistant Human Cancer Cells. Pharmaceuticals (Basel) 2020;13:E218. [PMID: 32872293 DOI: 10.3390/ph13090218] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
61 Miteva-Marcheva NN, Ivanov HY, Dimitrov DK, Stoyanova VK. Application of pharmacogenetics in oncology. Biomark Res 2020;8:32. [PMID: 32821392 DOI: 10.1186/s40364-020-00213-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
62 Paine MF. Natural Products: Experimental Approaches to Elucidate Disposition Mechanisms and Predict Pharmacokinetic Drug Interactions. Drug Metab Dispos 2020;48:956-62. [PMID: 32816868 DOI: 10.1124/dmd.120.000182] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
63 Montaser A, Markowicz-piasecka M, Sikora J, Jalkanen A, Huttunen KM. L-type amino acid transporter 1 (LAT1)-utilizing efflux transporter inhibitors can improve the brain uptake and apoptosis-inducing effects of vinblastine in cancer cells. International Journal of Pharmaceutics 2020;586:119585. [DOI: 10.1016/j.ijpharm.2020.119585] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
64 Singh J, Luqman S, Meena A. Emerging role of phytochemicals in targeting predictive, prognostic, and diagnostic biomarkers of lung cancer. Food Chem Toxicol 2020;144:111592. [PMID: 32702507 DOI: 10.1016/j.fct.2020.111592] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
65 Binnefeld M, Fritz S, Balzer V, Skalická V, Witzigmann D, Kauczor HU, Fricker G, Salomon JJ. Physicochemical and biopharmaceutical characterization of novel Matrix-Liposomes. Eur J Pharm Biopharm 2020;153:158-67. [PMID: 32522680 DOI: 10.1016/j.ejpb.2020.06.001] [Reference Citation Analysis]
66 Yao Q, Lin MT, Lan QH, Huang ZW, Zheng YW, Jiang X, Zhu YD, Kou L, Xu HL, Zhao YZ. In vitro and in vivo evaluation of didymin cyclodextrin inclusion complexes: characterization and chemosensitization activity. Drug Deliv 2020;27:54-65. [PMID: 31858849 DOI: 10.1080/10717544.2019.1704941] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
67 Mészáros JP, Poljarević JM, Szatmári I, Csuvik O, Fülöp F, Szoboszlai N, Spengler G, Enyedy ÉA. An 8-hydroxyquinoline-proline hybrid with multidrug resistance reversal activity and the solution chemistry of its half-sandwich organometallic Ru and Rh complexes. Dalton Trans 2020;49:7977-92. [PMID: 32500882 DOI: 10.1039/d0dt01256d] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
68 Mapletoft JPJ, St-Onge RJ, Guo B, Butler P, Masilamani TJ, D'costa L, Pritzker LB, Parissenti AM. The RNA disruption assay is superior to conventional drug sensitivity assays in detecting cytotoxic drugs. Sci Rep 2020;10:8671. [PMID: 32457334 DOI: 10.1038/s41598-020-65579-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
69 Lin YH, Lin KH, Yeh CT. Thyroid Hormone in Hepatocellular Carcinoma: Cancer Risk, Growth Regulation, and Anticancer Drug Resistance. Front Med (Lausanne) 2020;7:174. [PMID: 32528965 DOI: 10.3389/fmed.2020.00174] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
70 Santos AC, Costa D, Ferreira L, Guerra C, Pereira-Silva M, Pereira I, Peixoto D, Ferreira NR, Veiga F. Cyclodextrin-based delivery systems for in vivo-tested anticancer therapies. Drug Deliv Transl Res 2021;11:49-71. [PMID: 32441011 DOI: 10.1007/s13346-020-00778-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
71 Pillai SC, Borah A, Jindal A, Jacob EM, Yamamoto Y, Kumar DS. BioPerine Encapsulated Nanoformulation for Overcoming Drug-Resistant Breast Cancers. Asian J Pharm Sci 2020;15:701-12. [PMID: 33363626 DOI: 10.1016/j.ajps.2020.04.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
72 Nair B, Anto RJ, M S, Nath LR. Kaempferol-Mediated Sensitization Enhances Chemotherapeutic Efficacy of Sorafenib Against Hepatocellular Carcinoma: An In Silico and In Vitro Approach. Adv Pharm Bull 2020;10:472-6. [PMID: 32665908 DOI: 10.34172/apb.2020.058] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
73 Kaczor A, Nové M, Kincses A, Spengler G, Szymańska E, Latacz G, Handzlik J. Search for ABCB1 Modulators Among 2-Amine-5-Arylideneimidazolones as a New Perspective to Overcome Cancer Multidrug Resistance. Molecules 2020;25:E2258. [PMID: 32403277 DOI: 10.3390/molecules25092258] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
74 Reis MA, Matos AM, Duarte N, Ahmed OB, Ferreira RJ, Lage H, Ferreira MU. Epoxylathyrane Derivatives as MDR-Selective Compounds for Disabling Multidrug Resistance in Cancer. Front Pharmacol 2020;11:599. [PMID: 32457612 DOI: 10.3389/fphar.2020.00599] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
75 Fattahian M, Ghanadian M, Ali Z, Khan IA. Jatrophane and rearranged jatrophane-type diterpenes: biogenesis, structure, isolation, biological activity and SARs (1984-2019). Phytochem Rev 2020;:1-72. [PMID: 32292314 DOI: 10.1007/s11101-020-09667-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
76 Rolle F, Bincoletto V, Gazzano E, Rolando B, Lollo G, Stella B, Riganti C, Arpicco S. Coencapsulation of disulfiram and doxorubicin in liposomes strongly reverses multidrug resistance in breast cancer cells. International Journal of Pharmaceutics 2020;580:119191. [DOI: 10.1016/j.ijpharm.2020.119191] [Cited by in Crossref: 11] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
77 Chandra S, Michael Nguyen H, Wiltz K, Hall N, Chaudhry S, Olverson G, Mandal T, Dash S, Kundu A. Aptamer-functionalized Hybrid Nanoparticles to Enhance the Delivery of Doxorubicin into Breast Cancer Cells by Silencing P-glycoprotein. J Cancer Treatment Diagn 2020;4:1-13. [PMID: 32395707 DOI: 10.29245/2578-2967/2020/1.1176] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
78 Feng S, Zhou H, Wu D, Zheng D, Qu B, Liu R, Zhang C, Li Z, Xie Y, Luo HB. Nobiletin and its derivatives overcome multidrug resistance (MDR) in cancer: total synthesis and discovery of potent MDR reversal agents. Acta Pharm Sin B 2020;10:327-43. [PMID: 32082977 DOI: 10.1016/j.apsb.2019.07.007] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 11.0] [Reference Citation Analysis]
79 Jeyaraman S, Hanif EAM, Ab Mutalib NS, Jamal R, Abu N. Circular RNAs: Potential Regulators of Treatment Resistance in Human Cancers. Front Genet 2019;10:1369. [PMID: 32047511 DOI: 10.3389/fgene.2019.01369] [Cited by in Crossref: 12] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
80 Fathy Abd-Ellatef GE, Gazzano E, Chirio D, Hamed AR, Belisario DC, Zuddas C, Peira E, Rolando B, Kopecka J, Assem Said Marie M, Sapino S, Ramadan Fahmy S, Gallarate M, Abdel-Hamid AZ, Riganti C. Curcumin-Loaded Solid Lipid Nanoparticles Bypass P-Glycoprotein Mediated Doxorubicin Resistance in Triple Negative Breast Cancer Cells. Pharmaceutics 2020;12:E96. [PMID: 31991669 DOI: 10.3390/pharmaceutics12020096] [Cited by in Crossref: 23] [Cited by in F6Publishing: 41] [Article Influence: 11.5] [Reference Citation Analysis]
81 Nguyen PH, Sigdel KP, Schaefer KG, Mensah GAK, King GM, Roberts AG. The effects of anthracycline drugs on the conformational distribution of mouse P-glycoprotein explains their transport rate differences. Biochem Pharmacol 2020;174:113813. [PMID: 31954717 DOI: 10.1016/j.bcp.2020.113813] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
82 Costea T, Vlad OC, Miclea LC, Ganea C, Szöllősi J, Mocanu MM. Alleviation of Multidrug Resistance by Flavonoid and Non-Flavonoid Compounds in Breast, Lung, Colorectal and Prostate Cancer. Int J Mol Sci 2020;21:E401. [PMID: 31936346 DOI: 10.3390/ijms21020401] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 14.5] [Reference Citation Analysis]
83 Snyder S, Murundi S, Crawford L, Putnam D. Enabling P-glycoprotein inhibition in multidrug resistant cancer through the reverse targeting of a quinidine-PEG conjugate. Journal of Controlled Release 2020;317:291-9. [DOI: 10.1016/j.jconrel.2019.11.027] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
84 Ong CP, Lee WL, Tang YQ, Yap WH. Honokiol: A Review of Its Anticancer Potential and Mechanisms. Cancers (Basel) 2019;12:E48. [PMID: 31877856 DOI: 10.3390/cancers12010048] [Cited by in Crossref: 32] [Cited by in F6Publishing: 51] [Article Influence: 10.7] [Reference Citation Analysis]
85 Rathinaraj P, Muthusamy G, Prasad NR, Gunaseelan S, Kim B, Zhu S. Folate–Gold–Bilirubin Nanoconjugate Induces Apoptotic Death in Multidrug-Resistant Oral Carcinoma Cells. Eur J Drug Metab Pharmacokinet 2020;45:285-96. [DOI: 10.1007/s13318-019-00600-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
86 Muthu M, Kumar R, Syed Khaja AS, Gilthorpe JD, Persson JL, Nordström A. GLUL Ablation Can Confer Drug Resistance to Cancer Cells via a Malate-Aspartate Shuttle-Mediated Mechanism. Cancers (Basel) 2019;11:E1945. [PMID: 31817360 DOI: 10.3390/cancers11121945] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
87 Han SY, Kim ES, You BH, Chae HS, Lu Q, Chin YW, Ahn HC, Chung SJ, Lee K, Choi YH. Effect of treatment period with LC478, a disubstituted adamantayl derivative, on P-glycoprotein inhibition: its application to increase docetaxel absorption in rats. Xenobiotica 2020;50:863-74. [PMID: 31791185 DOI: 10.1080/00498254.2019.1700318] [Reference Citation Analysis]
88 Xu X, Li Q, Yu K, Murtaza G, Liu B. Baicalin-induced Cytotoxicity and Apoptosis in Multidrug-resistant MC3/5FU Mucoepidermoid Carcinoma Cell Line. LDDD 2019;16:1339-47. [DOI: 10.2174/157018081210151012121717] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
89 Camellato B, Roney IJ, Azizi A, Charlebois D, Kaern M. Engineered gene networks enable non‐genetic drug resistance and enhanced cellular robustness. Engineering Biology 2019;3:72-9. [DOI: 10.1049/enb.2019.0009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
90 Braunová, Kaňa, Kudláčová, Kostka, Bouček, Betka, Šírová, Etrych. Micelle-Forming Block Copolymers Tailored for Inhibition of P-gp-Mediated Multidrug Resistance: Structure to Activity Relationship. Pharmaceutics 2019;11:579. [DOI: 10.3390/pharmaceutics11110579] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
91 Kehinde I, Ramharack P, Nlooto M, Gordon M. The pharmacokinetic properties of HIV-1 protease inhibitors: A computational perspective on herbal phytochemicals. Heliyon 2019;5:e02565. [PMID: 31720444 DOI: 10.1016/j.heliyon.2019.e02565] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
92 Dei S, Braconi L, Romanelli MN, Teodori E. Recent advances in the search of BCRP- and dual P-gp/BCRP-based multidrug resistance modulators. Cancer Drug Resist 2019;2:710-43. [PMID: 35582565 DOI: 10.20517/cdr.2019.31] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
93 Dinić J, Podolski-Renić A, Jovanović M, Musso L, Tsakovska I, Pajeva I, Dallavalle S, Pešić M. Novel Heat Shock Protein 90 Inhibitors Suppress P-Glycoprotein Activity and Overcome Multidrug Resistance in Cancer Cells. Int J Mol Sci 2019;20:E4575. [PMID: 31527404 DOI: 10.3390/ijms20184575] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
94 Gzil A, Zarębska I, Bursiewicz W, Antosik P, Grzanka D, Szylberg Ł. Markers of pancreatic cancer stem cells and their clinical and therapeutic implications. Mol Biol Rep 2019;46:6629-45. [PMID: 31486978 DOI: 10.1007/s11033-019-05058-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 33] [Article Influence: 6.7] [Reference Citation Analysis]
95 Bazylińska U, Kulbacka J, Chodaczek G. Nanoemulsion Structural Design in Co-Encapsulation of Hybrid Multifunctional Agents: Influence of the Smart PLGA Polymers on the Nanosystem-Enhanced Delivery and Electro-Photodynamic Treatment. Pharmaceutics 2019;11:E405. [PMID: 31405247 DOI: 10.3390/pharmaceutics11080405] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
96 Espenschied ST, Cronan MR, Matty MA, Mueller O, Redinbo MR, Tobin DM, Rawls JF. Epithelial delamination is protective during pharmaceutical-induced enteropathy. Proc Natl Acad Sci U S A 2019;116:16961-70. [PMID: 31391308 DOI: 10.1073/pnas.1902596116] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
97 Lin MS, Hong TM, Chou TH, Yang SC, Chung WC, Weng CW, Tsai ML, Cheng TR, Chen JJW, Lee TC, Wong CH, Chein RJ, Yang PC. 4(1H)-quinolone derivatives overcome acquired resistance to anti-microtubule agents by targeting the colchicine site of β-tubulin. Eur J Med Chem 2019;181:111584. [PMID: 31419740 DOI: 10.1016/j.ejmech.2019.111584] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
98 Moradi Marjaneh R, Khazaei M, Ferns GA, Avan A, Aghaee-Bakhtiari SH. MicroRNAs as potential therapeutic targets to predict responses to oxaliplatin in colorectal cancer: From basic evidence to therapeutic implication. IUBMB Life 2019;71:1428-41. [PMID: 31322820 DOI: 10.1002/iub.2108] [Cited by in Crossref: 8] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
99 Willers C, Svitina H, Rossouw MJ, Swanepoel RA, Hamman JH, Gouws C. Models used to screen for the treatment of multidrug resistant cancer facilitated by transporter-based efflux. J Cancer Res Clin Oncol 2019;145:1949-76. [PMID: 31292714 DOI: 10.1007/s00432-019-02973-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
100 Zadorozhna M, Tataranni T, Mangieri D. Piperine: role in prevention and progression of cancer. Mol Biol Rep 2019;46:5617-29. [PMID: 31273611 DOI: 10.1007/s11033-019-04927-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
101 Salaroglio IC, Abate C, Rolando B, Battaglia L, Gazzano E, Colombino E, Costamagna C, Annovazzi L, Mellai M, Berardi F, Capucchio MT, Schiffer D, Riganti C. Validation of Thiosemicarbazone Compounds as P-Glycoprotein Inhibitors in Human Primary Brain-Blood Barrier and Glioblastoma Stem Cells. Mol Pharm 2019;16:3361-73. [PMID: 31265310 DOI: 10.1021/acs.molpharmaceut.9b00018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
102 Capelôa T, Benyahia Z, Zampieri LX, Blackman MCNM, Sonveaux P. Metabolic and non-metabolic pathways that control cancer resistance to anthracyclines. Semin Cell Dev Biol 2020;98:181-91. [PMID: 31112797 DOI: 10.1016/j.semcdb.2019.05.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
103 Shanmukhan NK, Radhakrishnan A, Maniarasan V, Kuppusamy G, Gideon S. Bioformulative concepts on intracellular organ specific bioavailability. Ther Deliv 2018;9:775-96. [PMID: 30277133 DOI: 10.4155/tde-2018-0032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
104 Qiu Q, Zhu J, Chen Q, Jiang Z, Xu J, Jiang X, Huang W, Liu Z, Ye J, Xu X. Discovery of aromatic amides with triazole-core as potent reversal agents against P-glycoprotein-mediated multidrug resistance. Bioorg Chem 2019;90:103083. [PMID: 31255991 DOI: 10.1016/j.bioorg.2019.103083] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
105 Vilar S, Sobarzo-sánchez E, Uriarte E. In Silico Prediction of P-glycoprotein Binding: Insights from Molecular Docking Studies. CMC 2019;26:1746-60. [DOI: 10.2174/0929867325666171129121924] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
106 Al-Akra L, Bae DH, Leck LYW, Richardson DR, Jansson PJ. The biochemical and molecular mechanisms involved in the role of tumor micro-environment stress in development of drug resistance. Biochim Biophys Acta Gen Subj 2019;1863:1390-7. [PMID: 31202693 DOI: 10.1016/j.bbagen.2019.06.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
107 Dei S, Braconi L, Trezza A, Menicatti M, Contino M, Coronnello M, Chiaramonte N, Manetti D, Perrone MG, Romanelli MN, Udomtanakunchai C, Colabufo NA, Bartolucci G, Spiga O, Salerno M, Teodori E. Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators. European Journal of Medicinal Chemistry 2019;172:71-94. [DOI: 10.1016/j.ejmech.2019.03.054] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
108 Jafari B, Pourseif MM, Barar J, Rafi MA, Omidi Y. Peptide-mediated drug delivery across the blood-brain barrier for targeting brain tumors. Expert Opinion on Drug Delivery 2019;16:583-605. [DOI: 10.1080/17425247.2019.1614911] [Cited by in Crossref: 21] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
109 Tang C, Luo C, Hua Y, Zhou K, Duan H, Ma F, Zhang Y, Li Y, Qiu D, Wang C. Placental P-glycoprotein inhibition enhances susceptibility to Di-(2-ethylhexyl)-phthalate induced cardiac malformations in mice: A possibly promising target for congenital heart defects prevention. PLoS One 2019;14:e0214873. [PMID: 31086358 DOI: 10.1371/journal.pone.0214873] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
110 Roma MG, Barosso IR, Miszczuk GS, Crocenzi FA, Pozzi EJS. Dynamic Localization of Hepatocellular Transporters: Role in Biliary Excretion and Impairment in Cholestasis. CMC 2019;26:1113-54. [DOI: 10.2174/0929867325666171205153204] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
111 Arnst KE, Wang Y, Lei ZN, Hwang DJ, Kumar G, Ma D, Parke DN, Chen Q, Yang J, White SW, Seagroves TN, Chen ZS, Miller DD, Li W. Colchicine Binding Site Agent DJ95 Overcomes Drug Resistance and Exhibits Antitumor Efficacy. Mol Pharmacol 2019;96:73-89. [PMID: 31043459 DOI: 10.1124/mol.118.114801] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
112 Rajendrakumar SK, Venu A, Revuri V, George Thomas R, Thirunavukkarasu GK, Zhang J, Vijayan V, Choi SY, Lee JY, Lee YK, Jeong YY, Park IK. Hyaluronan-Stabilized Redox-Sensitive Nanoassembly for Chemo-Gene Therapy and Dual T1/T2 MR Imaging in Drug-Resistant Breast Cancer Cells. Mol Pharm 2019;16:2226-34. [PMID: 30924664 DOI: 10.1021/acs.molpharmaceut.9b00189] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
113 Kapinova A, Kubatka P, Liskova A, Baranenko D, Kruzliak P, Matta M, Büsselberg D, Malicherova B, Zulli A, Kwon TK, Jezkova E, Blahutova D, Zubor P, Danko J. Controlling metastatic cancer: the role of phytochemicals in cell signaling. J Cancer Res Clin Oncol 2019;145:1087-109. [DOI: 10.1007/s00432-019-02892-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
114 Shirai F, Tsumura T, Yashiroda Y, Yuki H, Niwa H, Sato S, Chikada T, Koda Y, Washizuka K, Yoshimoto N, Abe M, Onuki T, Mazaki Y, Hirama C, Fukami T, Watanabe H, Honma T, Umehara T, Shirouzu M, Okue M, Kano Y, Watanabe T, Kitamura K, Shitara E, Muramatsu Y, Yoshida H, Mizutani A, Seimiya H, Yoshida M, Koyama H. Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors. J Med Chem 2019;62:3407-27. [DOI: 10.1021/acs.jmedchem.8b01888] [Cited by in Crossref: 18] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
115 Kazi J, Mukhopadhyay R, Sen R, Jha T, Ganguly S, Debnath MC. Design of 5-fluorouracil (5-FU) loaded, folate conjugated peptide linked nanoparticles, a potential new drug carrier for selective targeting of tumor cells. Medchemcomm 2019;10:559-72. [PMID: 31057736 DOI: 10.1039/c8md00565f] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
116 Rokavec M, Bouznad N, Hermeking H. Paracrine Induction of Epithelial-Mesenchymal Transition Between Colorectal Cancer Cells and its Suppression by a p53/miR-192/215/NID1 Axis. Cell Mol Gastroenterol Hepatol 2019;7:783-802. [PMID: 30831320 DOI: 10.1016/j.jcmgh.2019.02.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
117 Yan M, Wang J, Ren Y, Li L, He W, Zhang Y, Liu T, Li Z. Over-expression of FSIP1 promotes breast cancer progression and confers resistance to docetaxel via MRP1 stabilization. Cell Death Dis. 2019;10:204. [PMID: 30814489 DOI: 10.1038/s41419-018-1248-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
118 Shen C, Liu H, Dai W, Liu X, Liu J, Yu B. Specific N-demethylation of verapamil by cytochrome P450 from Streptomyces griseus ATCC 13273. Eng Life Sci 2019;19:292-301. [PMID: 32625009 DOI: 10.1002/elsc.201800116] [Reference Citation Analysis]
119 Jojo GM, Kuppusamy G. Scope of new formulation approaches in the repurposing of pioglitazone for the management of Alzheimer’s disease. J Clin Pharm Ther 2019;44:337-48. [DOI: 10.1111/jcpt.12808] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
120 Lee JJ, Lin HY, Chen CA, Lin CS, Wang LC. Development of an oligonucleotide microarray for simultaneous detection of two canine MDR1 genotypes and association between genotypes and chemotherapy side effects. J Vet Sci 2019;20:27-33. [PMID: 30481983 DOI: 10.4142/jvs.2019.20.1.27] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
121 Corti A, Dominici S, Piaggi S, Belcastro E, Chiu M, Taurino G, Pacini S, Bussolati O, Pompella A. γ-Glutamyltransferase enzyme activity of cancer cells modulates L-γ-glutamyl-p-nitroanilide (GPNA) cytotoxicity. Sci Rep 2019;9:891. [PMID: 30696905 DOI: 10.1038/s41598-018-37385-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
122 Guan J, Jiang Z, Wang M, Liu Y, Liu J, Yang Y, Ding T, Lu W, Gao C, Qian J, Zhan C. Short Peptide-Mediated Brain-Targeted Drug Delivery with Enhanced Immunocompatibility. Mol Pharm 2019;16:907-13. [PMID: 30666875 DOI: 10.1021/acs.molpharmaceut.8b01216] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
123 Riganti C, Contino M, Guglielmo S, Perrone MG, Salaroglio IC, Milosevic V, Giampietro R, Leonetti F, Rolando B, Lazzarato L, Colabufo NA, Fruttero R. Design, Biological Evaluation, and Molecular Modeling of Tetrahydroisoquinoline Derivatives: Discovery of A Potent P-Glycoprotein Ligand Overcoming Multidrug Resistance in Cancer Stem Cells. J Med Chem 2019;62:974-86. [DOI: 10.1021/acs.jmedchem.8b01655] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
124 Jardin I, Lopez JJ, Salido GM, Rosado JA. Store-Operated Ca2+ Entry in Breast Cancer Cells: Remodeling and Functional Role. Int J Mol Sci 2018;19:E4053. [PMID: 30558192 DOI: 10.3390/ijms19124053] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
125 Salaroglio IC, Gazzano E, Abdullrahman A, Mungo E, Castella B, Abd-Elrahman GEFA, Massaia M, Donadelli M, Rubinstein M, Riganti C, Kopecka J. Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer. J Exp Clin Cancer Res 2018;37:286. [PMID: 30482226 DOI: 10.1186/s13046-018-0967-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
126 Muthiah D, Henshaw GK, Debono AJ, Capuano B, Scammells PJ, Callaghan R. Overcoming P-Glycoprotein–Mediated Drug Resistance with Noscapine Derivatives. Drug Metab Dispos 2019;47:164-72. [DOI: 10.1124/dmd.118.083188] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
127 Aziz AUR, Geng C, Li W, Yu X, Qin K, Wang H, Liu B. Doxorubicin Induces ER Calcium Release via Src in Rat Ovarian Follicles. Toxicological Sciences 2019;168:171-8. [DOI: 10.1093/toxsci/kfy284] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
128 Zhao H, Huang Y, Shi J, Dai Y, Wu L, Zhou H. ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC. Front Pharmacol 2018;9:1312. [PMID: 30515095 DOI: 10.3389/fphar.2018.01312] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
129 Buondonno I, Gazzano E, Tavanti E, Chegaev K, Kopecka J, Fanelli M, Rolando B, Fruttero R, Gasco A, Hattinger C, Serra M, Riganti C. Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma. Cell Mol Life Sci 2019;76:609-25. [DOI: 10.1007/s00018-018-2967-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
130 Linville RM, DeStefano JG, Sklar MB, Xu Z, Farrell AM, Bogorad MI, Chu C, Walczak P, Cheng L, Mahairaki V, Whartenby KA, Calabresi PA, Searson PC. Human iPSC-derived blood-brain barrier microvessels: validation of barrier function and endothelial cell behavior. Biomaterials 2019;190-191:24-37. [PMID: 30391800 DOI: 10.1016/j.biomaterials.2018.10.023] [Cited by in Crossref: 67] [Cited by in F6Publishing: 86] [Article Influence: 16.8] [Reference Citation Analysis]
131 Gurjar R, Chan CYS, Curley P, Sharp J, Chiong J, Rannard S, Siccardi M, Owen A. Inhibitory Effects of Commonly Used Excipients on P-Glycoprotein in Vitro. Mol Pharm 2018;15:4835-42. [PMID: 30350641 DOI: 10.1021/acs.molpharmaceut.8b00482] [Cited by in Crossref: 23] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
132 Nunes AS, Costa EC, Barros AS, de Melo-Diogo D, Correia IJ. Establishment of 2D Cell Cultures Derived From 3D MCF-7 Spheroids Displaying a Doxorubicin Resistant Profile. Biotechnol J 2019;14:e1800268. [PMID: 30242980 DOI: 10.1002/biot.201800268] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
133 Liu K, Liu Y, Li C, Wang L, Liu J, Lei J. Self-Assembled pH and Redox Dual Responsive Carboxymethylcellulose-Based Polymeric Nanoparticles for Efficient Anticancer Drug Codelivery. ACS Biomater Sci Eng 2018;4:4200-7. [DOI: 10.1021/acsbiomaterials.8b00920] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
134 Sajid A, Lusvarghi S, Chufan EE, Ambudkar SV. Evidence for the critical role of transmembrane helices 1 and 7 in substrate transport by human P-glycoprotein (ABCB1). PLoS One 2018;13:e0204693. [PMID: 30265721 DOI: 10.1371/journal.pone.0204693] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
135 Huttunen J, Gynther M, Huttunen KM. Targeted efflux transporter inhibitors - A solution to improve poor cellular accumulation of anti-cancer agents. Int J Pharm 2018;550:278-89. [PMID: 30149128 DOI: 10.1016/j.ijpharm.2018.08.047] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
136 Miyake MM, Nocera A, Miyake MM. P-glycoprotein and chronic rhinosinusitis. World J Otorhinolaryngol Head Neck Surg 2018;4:169-74. [PMID: 30506047 DOI: 10.1016/j.wjorl.2018.07.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
137 Tang XL, Wu J, Lin BL, Cui S, Liu HM, Yu RT, Shen XD, Wang TW, Xia W. Near-infrared light-activated red-emitting upconverting nanoplatform for T1-weighted magnetic resonance imaging and photodynamic therapy. Acta Biomater 2018;74:360-73. [PMID: 29763715 DOI: 10.1016/j.actbio.2018.05.017] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
138 Salaroglio IC, Gazzano E, Kopecka J, Chegaev K, Costamagna C, Fruttero R, Guglielmo S, Riganti C. New Tetrahydroisoquinoline Derivatives Overcome Pgp Activity in Brain-Blood Barrier and Glioblastoma Multiforme in Vitro. Molecules 2018;23:E1401. [PMID: 29890725 DOI: 10.3390/molecules23061401] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
139 Gade DR, Makkapati A, Yarlagadda RB, Peters GJ, Sastry B, Rajendra Prasad V. Elucidation of chemosensitization effect of acridones in cancer cell lines: Combined pharmacophore modeling, 3D QSAR, and molecular dynamics studies. Computational Biology and Chemistry 2018;74:63-75. [DOI: 10.1016/j.compbiolchem.2018.02.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
140 Nikolaou M, Pavlopoulou A, Georgakilas AG, Kyrodimos E. The challenge of drug resistance in cancer treatment: a current overview. Clin Exp Metastasis 2018;35:309-18. [DOI: 10.1007/s10585-018-9903-0] [Cited by in Crossref: 147] [Cited by in F6Publishing: 195] [Article Influence: 36.8] [Reference Citation Analysis]
141 Babaer D, Amara S, Ivy M, Zhao Y, Lammers PE, Titze JM, Tiriveedhi V. High salt induces P-glycoprotein mediated treatment resistance in breast cancer cells through store operated calcium influx. Oncotarget 2018;9:25193-205. [PMID: 29861863 DOI: 10.18632/oncotarget.25391] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
142 Ríos-Colón L, Cajigas-Du Ross CK, Basu A, Elix C, Alicea-Polanco I, Sanchez TW, Radhakrishnan V, Chen CS, Casiano CA. Targeting the stress oncoprotein LEDGF/p75 to sensitize chemoresistant prostate cancer cells to taxanes. Oncotarget 2017;8:24915-31. [PMID: 28212536 DOI: 10.18632/oncotarget.15323] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
143 Su L, Fu L, Li Y, Yang F, Zhang M, Hu D. Disruption of the association between drug transporter and actin cytoskeleton abolishes drug resistance in hypertrophic scar. Oncotarget 2017;8:2617-27. [PMID: 27926506 DOI: 10.18632/oncotarget.13734] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
144 Asghari MH, Ghobadi E, Moloudizargari M, Fallah M, Abdollahi M. Does the use of melatonin overcome drug resistance in cancer chemotherapy? Life Sciences 2018;196:143-55. [DOI: 10.1016/j.lfs.2018.01.024] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 8.3] [Reference Citation Analysis]
145 Gibbs ME, Wilt LA, Ledwitch KV, Roberts AG. A Conformationally Gated Model of Methadone and Loperamide Transport by P-Glycoprotein. J Pharm Sci 2018;107:1937-47. [PMID: 29499278 DOI: 10.1016/j.xphs.2018.02.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
146 Rybinski B, Yun K. Addressing intra-tumoral heterogeneity and therapy resistance. Oncotarget 2016;7:72322-42. [PMID: 27608848 DOI: 10.18632/oncotarget.11875] [Cited by in Crossref: 38] [Cited by in F6Publishing: 44] [Article Influence: 9.5] [Reference Citation Analysis]
147 Yang Y, Guan D, Lei L, Lu J, Liu JQ, Yang G, Yan C, Zhai R, Tian J, Bi Y, Fu F, Wang H. H6, a novel hederagenin derivative, reverses multidrug resistance in vitro and in vivo. Toxicology and Applied Pharmacology 2018;341:98-105. [DOI: 10.1016/j.taap.2018.01.015] [Cited by in Crossref: 54] [Cited by in F6Publishing: 58] [Article Influence: 13.5] [Reference Citation Analysis]
148 Condic-Jurkic K, Subramanian N, Mark AE, O'Mara ML. The reliability of molecular dynamics simulations of the multidrug transporter P-glycoprotein in a membrane environment. PLoS One 2018;13:e0191882. [PMID: 29370310 DOI: 10.1371/journal.pone.0191882] [Cited by in Crossref: 15] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
149 Kopecka J, Porto S, Lusa S, Gazzano E, Salzano G, Pinzòn-Daza ML, Giordano A, Desiderio V, Ghigo D, De Rosa G, Caraglia M, Riganti C. Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: a combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors. Oncotarget 2016;7:20753-72. [PMID: 26980746 DOI: 10.18632/oncotarget.8012] [Cited by in Crossref: 22] [Cited by in F6Publishing: 29] [Article Influence: 5.5] [Reference Citation Analysis]
150 Gerhards NM, Rottenberg S. New tools for old drugs: Functional genetic screens to optimize current chemotherapy. Drug Resist Updat 2018;36:30-46. [PMID: 29499836 DOI: 10.1016/j.drup.2018.01.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
151 Lei X, Chen M, Li X, Huang M, Nie Q, Ma N, Chen H, Xu N, Ye W, Zhang D. A vascular disrupting agent overcomes tumor multidrug resistance by skewing macrophage polarity toward the M1 phenotype. Cancer Lett 2018;418:239-49. [PMID: 29337108 DOI: 10.1016/j.canlet.2018.01.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
152 Vágvölgyi M, Martins A, Kulmány Á, Zupkó I, Gáti T, Simon A, Tóth G, Hunyadi A. Nitrogen-containing ecdysteroid derivatives vs. multi-drug resistance in cancer: Preparation and antitumor activity of oximes, oxime ethers and a lactam. European Journal of Medicinal Chemistry 2018;144:730-9. [DOI: 10.1016/j.ejmech.2017.12.032] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
153 Liu T, Liu X, Xiong H, Xu C, Yao J, Zhu X, Zhou J, Yao J. Mechanisms of TPGS and its derivatives inhibiting P-glycoprotein efflux pump and application for reversing multidrug resistance in hepatocellular carcinoma. Polym Chem 2018;9:1827-39. [DOI: 10.1039/c8py00344k] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
154 Murata M, Kang J. Bisphenol A (BPA) and cell signaling pathways. Biotechnology Advances 2018;36:311-27. [DOI: 10.1016/j.biotechadv.2017.12.002] [Cited by in Crossref: 97] [Cited by in F6Publishing: 132] [Article Influence: 24.3] [Reference Citation Analysis]
155 Gazzano E, Rolando B, Chegaev K, Salaroglio IC, Kopecka J, Pedrini I, Saponara S, Sorge M, Buondonno I, Stella B, Marengo A, Valoti M, Brancaccio M, Fruttero R, Gasco A, Arpicco S, Riganti C. Folate-targeted liposomal nitrooxy-doxorubicin: An effective tool against P-glycoprotein-positive and folate receptor-positive tumors. Journal of Controlled Release 2018;270:37-52. [DOI: 10.1016/j.jconrel.2017.11.042] [Cited by in Crossref: 41] [Cited by in F6Publishing: 47] [Article Influence: 10.3] [Reference Citation Analysis]
156 Chae SW, Lee J, Park JH, Kwon Y, Na Y, Lee HJ. Intestinal P-glycoprotein inhibitors, benzoxanthone analogues. J Pharm Pharmacol 2018;70:234-41. [PMID: 29238994 DOI: 10.1111/jphp.12832] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
157 Gynther M, Proietti Silvestri I, Hansen JC, Hansen KB, Malm T, Ishchenko Y, Larsen Y, Han L, Kayser S, Auriola S, Petsalo A, Nielsen B, Pickering DS, Bunch L. Augmentation of Anticancer Drug Efficacy in Murine Hepatocellular Carcinoma Cells by a Peripherally Acting Competitive N-Methyl-d-aspartate (NMDA) Receptor Antagonist. J Med Chem 2017;60:9885-904. [PMID: 29205034 DOI: 10.1021/acs.jmedchem.7b01624] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
158 Hamdoun S, Fleischer E, Klinger A, Efferth T. Lawsone derivatives target the Wnt/β-catenin signaling pathway in multidrug-resistant acute lymphoblastic leukemia cells. Biochemical Pharmacology 2017;146:63-73. [DOI: 10.1016/j.bcp.2017.10.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
159 Rigalli JP, Scholz PN, Tocchetti GN, Ruiz ML, Weiss J. The phytoestrogens daidzein and equol inhibit the drug transporter BCRP/ABCG2 in breast cancer cells: potential chemosensitizing effect. Eur J Nutr 2019;58:139-50. [PMID: 29101532 DOI: 10.1007/s00394-017-1578-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
160 Bao Y, Kong M, Gao X, Yin M, Deng H, Tan Q, Wang Q, Tan S. pH-, redox dual-sensitive poly(β-amino ester)-g-TPGS copolymer nanoparticles for drug delivery and inhibition of multidrug resistance in cancer. Reactive and Functional Polymers 2017;120:131-8. [DOI: 10.1016/j.reactfunctpolym.2017.09.013] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
161 Sun D, Lv X, Wang X, Yu A, Wang Y. Mixed micelles based on a pH-sensitive prodrug and TPGS for enhancing drug efficacy against multidrug-resistant cancer cells. Colloids and Surfaces B: Biointerfaces 2017;159:419-26. [DOI: 10.1016/j.colsurfb.2017.07.082] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
162 Wang J, Lian Y, Gu Y, Wang H, Gu L, Huang Y, Zhou L, Huang Y. Synergistic effect of farnesyl transferase inhibitor lonafarnib combined with chemotherapeutic agents against the growth of hepatocellular carcinoma cells. Oncotarget 2017;8:105047-60. [PMID: 29285232 DOI: 10.18632/oncotarget.22086] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
163 Bitler BG, Watson ZL, Wheeler LJ, Behbakht K. PARP inhibitors: Clinical utility and possibilities of overcoming resistance. Gynecol Oncol 2017;147:695-704. [PMID: 29037806 DOI: 10.1016/j.ygyno.2017.10.003] [Cited by in Crossref: 115] [Cited by in F6Publishing: 116] [Article Influence: 23.0] [Reference Citation Analysis]
164 Yao Q, Choi JH, Dai Z, Wang J, Kim D, Tang X, Zhu L. Improving Tumor Specificity and Anticancer Activity of Dasatinib by Dual-Targeted Polymeric Micelles. ACS Appl Mater Interfaces 2017;9:36642-54. [PMID: 28960955 DOI: 10.1021/acsami.7b12233] [Cited by in Crossref: 48] [Cited by in F6Publishing: 54] [Article Influence: 9.6] [Reference Citation Analysis]
165 Pokharel D, Roseblade A, Oenarto V, Lu JF, Bebawy M. Proteins regulating the intercellular transfer and function of P-glycoprotein in multidrug-resistant cancer. Ecancermedicalscience 2017;11:768. [PMID: 29062386 DOI: 10.3332/ecancer.2017.768] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
166 Khan AR, Liu M, Khan MW, Zhai G. Progress in brain targeting drug delivery system by nasal route. J Control Release 2017;268:364-89. [PMID: 28887135 DOI: 10.1016/j.jconrel.2017.09.001] [Cited by in Crossref: 127] [Cited by in F6Publishing: 151] [Article Influence: 25.4] [Reference Citation Analysis]
167 Sharma A. Chemoresistance in cancer cells: exosomes as potential regulators of therapeutic tumor heterogeneity. Nanomedicine 2017;12:2137-48. [DOI: 10.2217/nnm-2017-0184] [Cited by in Crossref: 39] [Cited by in F6Publishing: 45] [Article Influence: 7.8] [Reference Citation Analysis]
168 Chaccour CJ, Hammann F, Alustiza M, Castejon S, Tarimo BB, Abizanda G, Irigoyen Barrio Á, Martí Soler H, Moncada R, Bilbao JI, Aldaz A, Maia M, Del Pozo JL. Cytochrome P450/ABC transporter inhibition simultaneously enhances ivermectin pharmacokinetics in the mammal host and pharmacodynamics in Anopheles gambiae. Sci Rep 2017;7:8535. [PMID: 28819225 DOI: 10.1038/s41598-017-08906-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
169 Mohamed LA, Markandaiah S, Bonanno S, Pasinelli P, Trotti D. Blood-Brain Barrier Driven Pharmacoresistance in Amyotrophic Lateral Sclerosis and Challenges for Effective Drug Therapies. AAPS J 2017;19:1600-14. [PMID: 28779378 DOI: 10.1208/s12248-017-0120-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
170 Pan M, Cui J, Jiao L, Ghaleb H, Liao C, Zhou J, Kairuki M, Lin H, Huang W, Qian H. Synthesis and biological evaluation of JL-A7 derivatives as potent ABCB1 inhibitors. Bioorganic & Medicinal Chemistry 2017;25:4194-202. [DOI: 10.1016/j.bmc.2017.06.015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
171 Marostica LL, de Barros ALB, Oliveira J, Salgado BS, Cassali GD, Leite EA, Cardoso VN, Lang KL, Caro MSB, Durán FJ, Schenkel EP, de Oliveira MC, Simões CMO. Antitumor effectiveness of a combined therapy with a new cucurbitacin B derivative and paclitaxel on a human lung cancer xenograft model. Toxicology and Applied Pharmacology 2017;329:272-81. [DOI: 10.1016/j.taap.2017.06.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
172 Singh MS, Tammam SN, Shetab Boushehri MA, Lamprecht A. MDR in cancer: Addressing the underlying cellular alterations with the use of nanocarriers. Pharmacol Res 2017;126:2-30. [PMID: 28760489 DOI: 10.1016/j.phrs.2017.07.023] [Cited by in Crossref: 23] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
173 Pounds R, Leonard S, Dawson C, Kehoe S. Repurposing itraconazole for the treatment of cancer. Oncol Lett 2017;14:2587-97. [PMID: 28927025 DOI: 10.3892/ol.2017.6569] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
174 Ma Y, Wang Y, Xu Z, Wang Y, Fallon JK, Liu F. Extreme low dose of 5-fluorouracil reverses MDR in cancer by sensitizing cancer associated fibroblasts and down-regulating P-gp. PLoS One 2017;12:e0180023. [PMID: 28662182 DOI: 10.1371/journal.pone.0180023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
175 Xiu C, Hua Z, Xiao BS, Tang WJ, Zhou HP, Liu XH. Novel benzopyran derivatives and their therapeutic applications: a patent review (2009-2016). Expert Opin Ther Pat 2017;27:1031-45. [PMID: 28627270 DOI: 10.1080/13543776.2017.1338687] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
176 Battistella C, Klok H. Reversion of P-gp-Mediated Drug Resistance in Ovarian Carcinoma Cells with PHPMA-Zosuquidar Conjugates. Biomacromolecules 2017;18:1855-65. [DOI: 10.1021/acs.biomac.7b00291] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
177 Reis MA, Ahmed OB, Spengler G, Molnár J, Lage H, Ferreira MU. Exploring Jolkinol D Derivatives To Overcome Multidrug Resistance in Cancer. J Nat Prod 2017;80:1411-20. [DOI: 10.1021/acs.jnatprod.6b01084] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
178 Pandey G, Mittapelly N, Valicherla GR, Shukla RP, Sharma S, Banala VT, Urandur S, Jajoriya AK, Mitra K, Mishra DP, Gayen JR, Mishra PR. P-gp modulatory acetyl-11-keto-β-boswellic acid based nanoemulsified carrier system for augmented oral chemotherapy of docetaxel. Colloids Surf B Biointerfaces 2017;155:276-86. [PMID: 28437753 DOI: 10.1016/j.colsurfb.2017.04.028] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
179 Omran Z, Scaife P, Stewart S, Rauch C. Physical and biological characteristics of multi drug resistance (MDR): An integral approach considering pH and drug resistance in cancer. Seminars in Cancer Biology 2017;43:42-8. [DOI: 10.1016/j.semcancer.2017.01.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
180 Nyquist MD, Prasad B, Mostaghel EA. Harnessing Solute Carrier Transporters for Precision Oncology. Molecules 2017;22:E539. [PMID: 28350329 DOI: 10.3390/molecules22040539] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
181 Spengler G, Kincses A, Gajdács M, Amaral L. New Roads Leading to Old Destinations: Efflux Pumps as Targets to Reverse Multidrug Resistance in Bacteria. Molecules 2017;22:E468. [PMID: 28294992 DOI: 10.3390/molecules22030468] [Cited by in Crossref: 88] [Cited by in F6Publishing: 97] [Article Influence: 17.6] [Reference Citation Analysis]
182 Bach DH, Hong JY, Park HJ, Lee SK. The role of exosomes and miRNAs in drug-resistance of cancer cells. Int J Cancer 2017;141:220-30. [PMID: 28240776 DOI: 10.1002/ijc.30669] [Cited by in Crossref: 123] [Cited by in F6Publishing: 147] [Article Influence: 24.6] [Reference Citation Analysis]
183 Wilt LA, Nguyen D, Roberts AG. Insights Into the Molecular Mechanism of Triptan Transport by P-glycoprotein. J Pharm Sci 2017;106:1670-9. [PMID: 28283434 DOI: 10.1016/j.xphs.2017.02.032] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
184 Ngo TD, Tran TD, Le MT, Thai KM. Machine learning-, rule- and pharmacophore-based classification on the inhibition of P-glycoprotein and NorA. SAR QSAR Environ Res 2016;27:747-80. [PMID: 27667641 DOI: 10.1080/1062936X.2016.1233137] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
185 Perez-Guerrero EE, Gamez-Nava JI, Muñoz-Valle JF, Cardona-Muñoz EG, Bonilla-Lara D, Fajardo-Robledo NS, Nava-Zavala AH, Garcia-Cobian TA, Rincón-Sánchez AR, Murillo-Vazquez JD, Cardona-Müller D, Vazquez-Villegas ML, Totsuka-Sutto SE, Gonzalez-Lopez L. Serum levels of P-glycoprotein and persistence of disease activity despite treatment in patients with systemic lupus erythematosus. Clin Exp Med 2018;18:109-17. [PMID: 28243944 DOI: 10.1007/s10238-017-0459-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
186 Teodori E, Dei S, Coronnello M, Floriddia E, Bartolucci G, Manetti D, Romanelli MN, Santo Domingo Porqueras D, Salerno M. N -alkanol- N -cyclohexanol amine aryl esters: Multidrug resistance (MDR) reversing agents with high potency and efficacy. European Journal of Medicinal Chemistry 2017;127:586-98. [DOI: 10.1016/j.ejmech.2017.01.019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
187 El-Awady R, Saleh E, Hashim A, Soliman N, Dallah A, Elrasheed A, Elakraa G. The Role of Eukaryotic and Prokaryotic ABC Transporter Family in Failure of Chemotherapy. Front Pharmacol 2016;7:535. [PMID: 28119610 DOI: 10.3389/fphar.2016.00535] [Cited by in Crossref: 43] [Cited by in F6Publishing: 63] [Article Influence: 8.6] [Reference Citation Analysis]
188 El-Araby ME, Omar AM, Khayat MT, Assiri HA, Al-Abd AM. Molecular Mimics of Classic P-Glycoprotein Inhibitors as Multidrug Resistance Suppressors and Their Synergistic Effect on Paclitaxel. PLoS One 2017;12:e0168938. [PMID: 28068430 DOI: 10.1371/journal.pone.0168938] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
189 Savage P. Chemotherapy curable malignancies and cancer stem cells: A biological review and hypothesis. BMC Cancer. 2016;16:906. [PMID: 27871274 DOI: 10.1186/s12885-016-2956-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
190 Ducreux M, Bennouna J, Adenis A, Conroy T, Lièvre A, Portales F, Jeanes J, Li L, Romano A. Efficacy and safety of nab-paclitaxel in patients with previously treated metastatic colorectal cancer: a phase II COLO-001 trial. Cancer Chemother Pharmacol 2017;79:9-16. [DOI: 10.1007/s00280-016-3193-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
191 Jacus MO, Daryani VM, Harstead KE, Patel YT, Throm SL, Stewart CF. Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature. Clin Pharmacokinet 2016;55:297-311. [PMID: 26293618 DOI: 10.1007/s40262-015-0319-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 4.2] [Reference Citation Analysis]
192 Alharbi HA, Alcorn J, Al-mousa A, Giesy JP, Wiseman SB. Toxicokinetics and toxicodynamics of chlorpyrifos is altered in embryos of Japanese medaka exposed to oil sands process-affected water: evidence for inhibition of P-glycoprotein: OSPW inhibits P-gp. J Appl Toxicol 2017;37:591-601. [DOI: 10.1002/jat.3397] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
193 Mangraviti A, Gullotti D, Tyler B, Brem H. Nanobiotechnology-based delivery strategies: New frontiers in brain tumor targeted therapies. Journal of Controlled Release 2016;240:443-53. [DOI: 10.1016/j.jconrel.2016.03.031] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
194 Wijdeven RH, Pang B, Assaraf YG, Neefjes J. Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics. Drug Resistance Updates 2016;28:65-81. [DOI: 10.1016/j.drup.2016.07.001] [Cited by in Crossref: 101] [Cited by in F6Publishing: 113] [Article Influence: 16.8] [Reference Citation Analysis]
195 Mahmoodi NO, Ghavidast A, Amirmahani N. A comparative study on the nanoparticles for improved drug delivery systems. Journal of Photochemistry and Photobiology B: Biology 2016;162:681-93. [DOI: 10.1016/j.jphotobiol.2016.07.037] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 4.8] [Reference Citation Analysis]
196 Kopecka J, Porto S, Lusa S, Gazzano E, Salzano G, Giordano A, Desiderio V, Ghigo D, Caraglia M, De Rosa G, Riganti C. Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells. Oncotarget 2015;6:31461-78. [PMID: 26372812 DOI: 10.18632/oncotarget.5058] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
197 Chennell G, Willows RJ, Warren SC, Carling D, French PM, Dunsby C, Sardini A. Imaging of Metabolic Status in 3D Cultures with an Improved AMPK FRET Biosensor for FLIM. Sensors (Basel) 2016;16:E1312. [PMID: 27548185 DOI: 10.3390/s16081312] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
198 Pan ZZ, Wang HY, Zhang M, Lin TT, Zhang WY, Zhao PF, Tang YS, Xiong Y, Zeng YE, Huang YZ. Nuclear-targeting TAT-PEG-Asp8-doxorubicin polymeric nanoassembly to overcome drug-resistant colon cancer. Acta Pharmacol Sin 2016;37:1110-20. [PMID: 27292613 DOI: 10.1038/aps.2016.48] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
199 Reis MA, Ahmed OB, Spengler G, Molnár J, Lage H, Ferreira MU. Jatrophane diterpenes and cancer multidrug resistance – ABCB1 efflux modulation and selective cell death induction. Phytomedicine 2016;23:968-78. [DOI: 10.1016/j.phymed.2016.05.007] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
200 Ngo TD, Tran TD, Le MT, Thai KM. Computational predictive models for P-glycoprotein inhibition of in-house chalcone derivatives and drug-bank compounds. Mol Divers 2016;20:945-61. [PMID: 27431577 DOI: 10.1007/s11030-016-9688-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
201 Fusi F, Durante M, Spiga O, Trezza A, Frosini M, Floriddia E, Teodori E, Dei S, Saponara S. In vitro and in silico analysis of the vascular effects of asymmetrical N,N-bis(alkanol)amine aryl esters, novel multidrug resistance-reverting agents. Naunyn Schmiedebergs Arch Pharmacol 2016;389:1033-43. [PMID: 27351883 DOI: 10.1007/s00210-016-1266-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
202 Niazi M, Zakeri-Milani P, Najafi Hajivar S, Soleymani Goloujeh M, Ghobakhlou N, Shahbazi Mojarrad J, Valizadeh H. Nano-based strategies to overcome p-glycoprotein-mediated drug resistance. Expert Opin Drug Metab Toxicol 2016;12:1021-33. [PMID: 27267126 DOI: 10.1080/17425255.2016.1196186] [Cited by in Crossref: 28] [Cited by in F6Publishing: 34] [Article Influence: 4.7] [Reference Citation Analysis]
203 Yan T, Li D, Li J, Cheng F, Cheng J, Huang Y, He J. Effective co-delivery of doxorubicin and curcumin using a glycyrrhetinic acid-modified chitosan-cystamine-poly(ε-caprolactone) copolymer micelle for combination cancer chemotherapy. Colloids Surf B Biointerfaces 2016;145:526-38. [PMID: 27281238 DOI: 10.1016/j.colsurfb.2016.05.070] [Cited by in Crossref: 38] [Cited by in F6Publishing: 43] [Article Influence: 6.3] [Reference Citation Analysis]
204 Guan H, Zhao P, Dai Z, Liu X, Wang X. SH3GL1 inhibition reverses multidrug resistance in colorectal cancer cells by downregulation of MDR1/P-glycoprotein via EGFR/ERK/AP-1 pathway. Tumor Biol 2016;37:12153-60. [DOI: 10.1007/s13277-016-5092-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
205 Han L, Guo X, Bian H, Yang L, Chen Z, Zang W, Yang J. Guizhi Fuling Wan, a Traditional Chinese Herbal Formula, Sensitizes Cisplatin-Resistant Human Ovarian Cancer Cells through Inactivation of the PI3K/AKT/mTOR Pathway. Evid Based Complement Alternat Med 2016;2016:4651949. [PMID: 27293459 DOI: 10.1155/2016/4651949] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
206 Kovács D, Szőke K, Igaz N, Spengler G, Molnár J, Tóth T, Madarász D, Rázga Z, Kónya Z, Boros IM, Kiricsi M. Silver nanoparticles modulate ABC transporter activity and enhance chemotherapy in multidrug resistant cancer. Nanomedicine: Nanotechnology, Biology and Medicine 2016;12:601-10. [DOI: 10.1016/j.nano.2015.10.015] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 5.3] [Reference Citation Analysis]
207 Callies O, Sánchez-cañete MP, Gamarro F, Jiménez IA, Castanys S, Bazzocchi IL. Optimization by Molecular Fine Tuning of Dihydro-β-agarofuran Sesquiterpenoids as Reversers of P-Glycoprotein-Mediated Multidrug Resistance. J Med Chem 2016;59:1880-90. [DOI: 10.1021/acs.jmedchem.5b01429] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
208 Zhitomirsky B, Assaraf YG. Lysosomes as mediators of drug resistance in cancer. Drug Resistance Updates 2016;24:23-33. [DOI: 10.1016/j.drup.2015.11.004] [Cited by in Crossref: 216] [Cited by in F6Publishing: 249] [Article Influence: 36.0] [Reference Citation Analysis]
209 Chen S, Yang K, Tuguntaev RG, Mozhi A, Zhang J, Wang PC, Liang XJ. Targeting tumor microenvironment with PEG-based amphiphilic nanoparticles to overcome chemoresistance. Nanomedicine 2016;12:269-86. [PMID: 26707818 DOI: 10.1016/j.nano.2015.10.020] [Cited by in Crossref: 57] [Cited by in F6Publishing: 68] [Article Influence: 8.1] [Reference Citation Analysis]
210 Melguizo C, Cabeza L, Prados J, Ortiz R, Caba O, Rama AR, Delgado ÁV, Arias JL. Enhanced antitumoral activity of doxorubicin against lung cancer cells using biodegradable poly(butylcyanoacrylate) nanoparticles. Drug Des Devel Ther 2015;9:6433-44. [PMID: 26715840 DOI: 10.2147/DDDT.S92273] [Cited by in Crossref: 5] [Cited by in F6Publishing: 17] [Article Influence: 0.7] [Reference Citation Analysis]
211 Lu JF, Pokharel D, Bebawy M. MRP1 and its role in anticancer drug resistance. Drug Metab Rev 2015;47:406-19. [PMID: 26541366 DOI: 10.3109/03602532.2015.1105253] [Cited by in Crossref: 64] [Cited by in F6Publishing: 77] [Article Influence: 9.1] [Reference Citation Analysis]
212 Mealey KL, Fidel J. P-glycoprotein mediated drug interactions in animals and humans with cancer. J Vet Intern Med 2015;29:1-6. [PMID: 25619511 DOI: 10.1111/jvim.12525] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 5.9] [Reference Citation Analysis]
213 Assanhou AG, Li W, Zhang L, Xue L, Kong L, Sun H, Mo R, Zhang C. Reversal of multidrug resistance by co-delivery of paclitaxel and lonidamine using a TPGS and hyaluronic acid dual-functionalized liposome for cancer treatment. Biomaterials 2015;73:284-95. [PMID: 26426537 DOI: 10.1016/j.biomaterials.2015.09.022] [Cited by in Crossref: 124] [Cited by in F6Publishing: 148] [Article Influence: 17.7] [Reference Citation Analysis]
214 Hao T, Chen D, Liu K, Qi Y, Tian Y, Sun P, Liu Y, Li Z. Micelles of d -α-Tocopheryl Polyethylene Glycol 2000 Succinate (TPGS 2K) for Doxorubicin Delivery with Reversal of Multidrug Resistance. ACS Appl Mater Interfaces 2015;7:18064-75. [DOI: 10.1021/acsami.5b04995] [Cited by in Crossref: 43] [Cited by in F6Publishing: 50] [Article Influence: 6.1] [Reference Citation Analysis]
215 Koot D, Cromarty D. Anticancer efficacy and toxicokinetics of a novel paclitaxel-clofazimine nanoparticulate co-formulation. Drug Deliv Transl Res 2015;5:257-67. [PMID: 25795051 DOI: 10.1007/s13346-015-0222-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
216 Pantziarka P, Sukhatme V, Bouche G, Meheus L, Sukhatme VP. Repurposing Drugs in Oncology (ReDO)-itraconazole as an anti-cancer agent. Ecancermedicalscience 2015;9:521. [PMID: 25932045 DOI: 10.3332/ecancer.2015.521] [Cited by in Crossref: 34] [Cited by in F6Publishing: 43] [Article Influence: 4.9] [Reference Citation Analysis]
217 Kell DB, Swainston N, Pir P, Oliver SG. Membrane transporter engineering in industrial biotechnology and whole cell biocatalysis. Trends in Biotechnology 2015;33:237-46. [DOI: 10.1016/j.tibtech.2015.02.001] [Cited by in Crossref: 121] [Cited by in F6Publishing: 124] [Article Influence: 17.3] [Reference Citation Analysis]
218 Davis PJ, Incerpi S, Lin HY, Tang HY, Sudha T, Mousa SA. Thyroid hormone and P-glycoprotein in tumor cells. Biomed Res Int 2015;2015:168427. [PMID: 25866761 DOI: 10.1155/2015/168427] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
219 Teng YN, Hsieh YW, Hung CC, Lin HY. Demethoxycurcumin modulates human P-glycoprotein function via uncompetitive inhibition of ATPase hydrolysis activity. J Agric Food Chem 2015;63:847-55. [PMID: 25594233 DOI: 10.1021/jf5042307] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
220 Schuetz JD, Swaan PW, Tweedie DJ. The role of transporters in toxicity and disease. Drug Metab Dispos 2014;42:541-5. [PMID: 24598705 DOI: 10.1124/dmd.114.057539] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
221 Niazi M, Zakeri-Milani P, Soleymani-Goloujeh M, Mohammadi A, Sarfraz M, Löbenberg R, Najafi-Hajivar S, Shahbazi-Mojarrad J, Farshbaf M, Valizadeh H. Effects of self-assembled cell-penetrating peptides and their nano-complexes on ABCB1 expression and activity. Iran J Basic Med Sci 2021;24:383-90. [PMID: 33995950 DOI: 10.22038/ijbms.2021.51675.11727] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
222 Norouzi-Barough L, Sarookhani M, Salehi R, Sharifi M, Moghbelinejad S. CRISPR/Cas9, a new approach to successful knockdown of ABCB1/P-glycoprotein and reversal of chemosensitivity in human epithelial ovarian cancer cell line. Iran J Basic Med Sci 2018;21:181-7. [PMID: 29456815 DOI: 10.22038/IJBMS.2017.25145.6230] [Cited by in F6Publishing: 14] [Reference Citation Analysis]